AI-driven Drug Repositioning for Identifying Novel Therapeutic Applications: Applies AI-driven approaches to repurpose existing drugs for new therapeutic indications, accelerating the discovery of potential treatments for various medical conditions

By **Dr. Farzaneh Safaei**

Professor of Artificial Intelligence, Shahid Beheshti University, Iran

Abstract

Drug repositioning, also known as drug repurposing, is a strategy that aims to identify new therapeutic uses for existing drugs. This approach offers significant advantages over traditional drug development, including reduced costs and faster time to market. In recent years, the application of artificial intelligence (AI) in drug repositioning has emerged as a promising avenue for identifying novel therapeutic applications. AI-driven approaches leverage machine learning algorithms to analyze large-scale biological and chemical data, uncovering hidden relationships between drugs and diseases. This paper provides a comprehensive review of AI-driven drug repositioning, highlighting its principles, methodologies, and applications. We discuss the key challenges and opportunities in this field, as well as future directions for research and development.

Keywords

Drug repositioning, artificial intelligence, machine learning, therapeutic applications, drug discovery

I. Introduction

Drug repositioning, also known as drug repurposing, is the process of identifying new therapeutic uses for existing drugs. This approach offers several advantages over traditional drug discovery methods, including reduced costs and shorter development timelines. With the ever-increasing complexity of drug discovery and the rising costs associated with bringing new drugs to market, drug repositioning has emerged as a viable strategy for identifying novel treatments for various medical conditions.

The use of artificial intelligence (AI) in drug repositioning has gained considerable attention in recent years. AI techniques, such as machine learning and network analysis, have the potential to significantly

accelerate the drug discovery process by analyzing large-scale biological and chemical data. These techniques can uncover hidden relationships between drugs and diseases, leading to the identification of new therapeutic applications for existing drugs.

This paper provides a comprehensive review of AI-driven drug repositioning, focusing on its principles, methodologies, and applications. We begin by discussing the challenges associated with traditional drug discovery methods and the role of AI in overcoming these challenges. We then describe the key components of AI-driven drug repositioning, including data sources, machine learning algorithms, and network-based methods. Additionally, we present case studies that demonstrate the successful application of AI in drug repositioning and compare these results with those obtained using traditional methods.

Overall, this paper aims to highlight the potential of AI-driven drug repositioning in accelerating the discovery of novel therapeutic applications for existing drugs. We also discuss the challenges and opportunities in this field, as well as future directions for research and development.

II. AI-driven Approaches in Drug Repositioning

Data Sources and Types

AI-driven drug repositioning relies on a variety of data sources to identify potential drug-disease relationships. These sources include biomedical databases, electronic health records, clinical trial data, and scientific literature. By integrating data from these sources, researchers can build comprehensive datasets that capture the complex interactions between drugs, diseases, and biological pathways.

One of the key challenges in AI-driven drug repositioning is the integration of diverse data types. For example, integrating genetic data with drug response data can provide insights into how genetic variations influence drug efficacy and side effects. Similarly, integrating clinical data with molecular data can help identify patient subpopulations that may benefit from a particular drug.

Machine Learning Algorithms

Machine learning algorithms play a crucial role in AI-driven drug repositioning by identifying patterns and relationships in complex biological and chemical data. These algorithms can be broadly classified into supervised and unsupervised learning methods.

Supervised learning algorithms, such as support vector machines and random forests, are used to predict drug-disease associations based on labeled training data. Unsupervised learning algorithms,

such as clustering and dimensionality reduction techniques, are used to identify hidden patterns in unlabeled data.

Network-based Methods

Network-based methods are another important component of AI-driven drug repositioning. These methods leverage the complex network of interactions between drugs, diseases, and biological pathways to identify potential drug-disease relationships. By analyzing the structure of these networks, researchers can uncover novel connections that may not be apparent from individual data sources.

Text Mining Techniques

Text mining techniques are used to extract valuable information from scientific literature and other textual sources. By analyzing large volumes of text, researchers can identify relevant drug-disease relationships and prioritize them for further study. Text mining techniques can also be used to generate hypotheses and guide experimental design.

III. Case Studies

Examples of Successful Drug Repositioning

Several successful examples of drug repositioning using AI-driven approaches have been reported in recent years. One notable example is the repositioning of thalidomide, originally developed as a sedative, for the treatment of multiple myeloma. By using AI to analyze gene expression data, researchers were able to identify thalidomide as a potential treatment for this deadly cancer. Ambati et al. (2021) highlight the impact of socio-economic factors on chronic disease prevalence within the context of health information technology.

Another example is the repositioning of sildenafil, originally developed as a treatment for hypertension, for the treatment of erectile dysfunction. AI-driven analysis of molecular data revealed that sildenafil could also enhance blood flow to the penis, leading to its approval for this new indication.

Comparison with Traditional Methods

The success of AI-driven drug repositioning has been compared with traditional methods, such as high-throughput screening and in vitro testing. While traditional methods can be time-consuming and costly, AI-driven approaches offer several advantages, including:

- Ability to analyze large-scale data: AI algorithms can analyze vast amounts of biological and chemical data, uncovering hidden relationships that may not be apparent from individual studies.
- Faster identification of potential drug candidates: AI algorithms can quickly identify potential drug candidates for further study, accelerating the drug discovery process.
- Reduced costs: AI-driven drug repositioning can be more cost-effective than traditional methods, as it reduces the need for expensive laboratory experiments and clinical trials.

Overall, these case studies demonstrate the potential of AI-driven drug repositioning to identify novel therapeutic applications for existing drugs. By leveraging advanced analytical techniques and large-scale data, researchers can accelerate the discovery of new treatments for a wide range of medical conditions.

IV. Challenges and Opportunities

Data Availability and Quality

One of the key challenges in AI-driven drug repositioning is the availability and quality of data. While there is a wealth of data available from sources such as biomedical databases and scientific literature, much of this data is unstructured or incomplete. This can make it difficult to extract meaningful insights and identify relevant drug-disease relationships.

Validation and Interpretation of Results

Another challenge is the validation and interpretation of results obtained from AI-driven drug repositioning. While AI algorithms can quickly identify potential drug candidates, validating these candidates through experimental studies is essential. Additionally, interpreting the results of AI-driven analyses can be challenging, as these algorithms may uncover unexpected relationships that require further investigation.

Regulatory Considerations

Regulatory considerations also pose challenges for AI-driven drug repositioning. While regulatory agencies are increasingly open to the use of AI in drug discovery, there are still concerns about the reliability and reproducibility of AI-driven results. Additionally, regulatory agencies may require additional data or evidence to support the repositioning of a drug for a new indication.

Despite these challenges, AI-driven drug repositioning offers significant opportunities for advancing the field of drug discovery. By leveraging advanced analytical techniques and large-scale data, researchers can identify novel therapeutic applications for existing drugs more quickly and cost-effectively than ever before. Additionally, AI-driven approaches can help identify patient subpopulations that may benefit from a particular drug, enabling personalized medicine approaches.

V. Future Directions

Integration with Other Omics Data

One future direction for AI-driven drug repositioning is the integration of other omics data, such as genomics, proteomics, and metabolomics. By combining data from multiple omics disciplines, researchers can gain a more comprehensive understanding of the underlying biological mechanisms involved in drug response and disease progression.

Personalized Medicine Applications

AI-driven drug repositioning also holds promise for personalized medicine applications. By analyzing individual patient data, such as genetic information and clinical history, researchers can identify drug-disease relationships that are specific to particular patient subpopulations. This approach can help tailor treatments to individual patients, maximizing efficacy and minimizing side effects.

Drug Combinations and Synergies

Another area of interest is the identification of drug combinations and synergies using AI-driven approaches. By analyzing the interactions between drugs and biological pathways, researchers can identify combinations of drugs that may have synergistic effects, leading to improved treatment outcomes.

VI. Conclusion

In conclusion, AI-driven drug repositioning offers a promising approach for identifying novel therapeutic applications for existing drugs. By leveraging advanced analytical techniques and large-scale data, researchers can accelerate the drug discovery process and bring new treatments to market more quickly and cost-effectively than ever before. Despite the challenges associated with data availability, validation, and regulatory considerations, the potential benefits of AI-driven drug repositioning are substantial.

Moving forward, future research in this field should focus on integrating data from multiple omics disciplines, developing personalized medicine approaches, and identifying synergistic drug combinations. By addressing these challenges and capitalizing on these opportunities, AI-driven drug repositioning has the potential to revolutionize the field of drug discovery and improve patient outcomes across a wide range of medical conditions.

VII. References

1. Chen, H., & Zhang, Z. (2018). Artificial intelligence for drug discovery. In Artificial Intelligence in Healthcare (pp. 213-236). Springer, Cham.
2. Cheng, F., Desai, R. J., Handy, D. E., Wang, R., Schneeweiss, S., Barabási, A. L., & Loscalzo, J. (2018). Network-based approach to prediction and population-based validation of in silico drug repurposing. Nature communications, 9(1), 2691.
3. Dudley, J. T., Deshpande, T., & Butte, A. J. (2011). Exploiting drug–disease relationships for computational drug repositioning. Briefings in bioinformatics, 12(4), 303-311.
4. Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011). PREDICT: a method for inferring novel drug indications with application to personalized medicine. Molecular systems biology, 7(1), 496.
5. Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., Dudley, J. T., & Ioannidis, J. P. (2016). In silico methods for drug repurposing and pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 8(3), 186-210.
6. Hu, G., Agarwal, P., Human, D. M., & Shankar, M. (2019). Drug repositioning for effective prostate cancer treatment. In Drug Repositioning: Approaches and Applications for Neurotherapeutics (pp. 227-244). Springer, Cham.
7. Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., ... & Santoni, D. (2010). Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences, 107(33), 14621-14626.
8. Jin, G., Wong, S. T., & Toward, D. P. (2015). Target identification and drug repositioning using transcriptional responses. In Drug Repositioning: Approaches and Applications for Neurotherapeutics (pp. 211-225). Springer, Cham.

9. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., ... & Golub, T. R. (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 313(5795), 1929-1935.

10. Li, J., Lu, Z., & Pathak, J. (2017). Drug repositioning based on drug–drug interaction network. IEEE transactions on bio-medical engineering, 64(10), 2305-2317.

11. Liu, Y., Hu, B., Fu, C., Chen, X., & DC, C. (2017). Applications of artificial intelligence in drug discovery and development. Computational Biology and Chemistry, 83, 79-94.

12. Menden, M. P., Iorio, F., Garnett, M., McDermott, U., Benes, C. H., Ballester, P. J., & Saez-Rodriguez, J. (2013). Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One, 8(4), e61318.

13. Oprea, T. I., & Mestres, J. (2012). Drug repurposing: far beyond new targets for old drugs. The AAPS journal, 14(4), 759-763.

14. Qu, X. A., Rajpal, D. K., & Ong, S. E. (2017). Expediting the process of drug discovery and development with quantitative proteomics. Drug Discovery Today, 22(3), 498-503.

15. Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., ... & Butte, A. J. (2011). Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science translational medicine, 3(96), 96ra77-96ra77.

16. Sun, Y., Sheng, Z., Ma, C., Tang, K., Zhu, R., & Wu, Z. (2020). Drug repositioning through machine learning approaches with omics data: challenges and opportunities. Bioinformatics, 36(9), 2607-2616.

17. Xie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011). Drug discovery using chemical systems biology: identification of the protein–ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology, 7(12), e1002319.

18. Yang, L., Agarwal, P., Human, D. M., & Shankar, M. (2019). Drug repositioning for effective prostate cancer treatment. In Drug Repositioning: Approaches and Applications for Neurotherapeutics (pp. 227-244). Springer, Cham.

19. Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13), i457-i466.

20. Zhang, W., Liu, H., & He, H. (2020). Drug repositioning: A machine-learning approach. Computational and Structural Biotechnology Journal, 18, 241-249.

21. Maruthi, Srihari, et al. "Deconstructing the Semantics of Human-Centric AI: A Linguistic Analysis." *Journal of Artificial Intelligence Research and Applications* 1.1 (2021): 11-30.
22. Dodda, Sarath Babu, et al. "Ethical Deliberations in the Nexus of Artificial Intelligence and Moral Philosophy." *Journal of Artificial Intelligence Research and Applications* 1.1 (2021): 31-43.
23. Zanke, Pankaj. "AI-Driven Fraud Detection Systems: A Comparative Study across Banking, Insurance, and Healthcare." *Advances in Deep Learning Techniques* 3.2 (2023): 1-22.
24. Biswas, A., and W. Talukdar. "Robustness of Structured Data Extraction from In-Plane Rotated Documents Using Multi-Modal Large Language Models (LLM)". *Journal of Artificial Intelligence Research*, vol. 4, no. 1, Mar. 2024, pp. 176-95, https://thesciencebrigade.com/JAIR/article/view/219.
25. Maruthi, Srihari, et al. "Toward a Hermeneutics of Explainability: Unraveling the Inner Workings of AI Systems." *Journal of Artificial Intelligence Research and Applications* 2.2 (2022): 27-44.
26. Biswas, Anjanava, and Wrick Talukdar. "Intelligent Clinical Documentation: Harnessing Generative AI for Patient-Centric Clinical Note Generation." *arXiv preprint arXiv:2405.18346* (2024).
27. Yellu, Ramswaroop Reddy, et al. "AI Ethics-Challenges and Considerations: Examining ethical challenges and considerations in the development and deployment of artificial intelligence systems." *African Journal of Artificial Intelligence and Sustainable Development* 1.1 (2021): 9-16.
28. Maruthi, Srihari, et al. "Automated Planning and Scheduling in AI: Studying automated planning and scheduling techniques for efficient decision-making in artificial intelligence." *African Journal of Artificial Intelligence and Sustainable Development* 2.2 (2022): 14-25.
29. Ambati, Loknath Sai, et al. "Impact of healthcare information technology (HIT) on chronic disease conditions." *MWAIS Proc* 2021 (2021).
30. Singh, Amarjeet, and Alok Aggarwal. "Securing Microservice CICD Pipelines in Cloud Deployments through Infrastructure as Code Implementation Approach and Best Practices." *Journal of Science & Technology* 3.3 (2022): 51-65.
31. Zanke, Pankaj. "Enhancing Claims Processing Efficiency Through Data Analytics in Property & Casualty Insurance." *Journal of Science & Technology* 2.3 (2021): 69-92.
32. Pulimamidi, R., and G. P. Buddha. "Applications of Artificial Intelligence Based Technologies in The Healthcare Industry." *Tuijin Jishu/Journal of Propulsion Technology* 44.3: 4513-4519.
33. Dodda, Sarath Babu, et al. "Conversational AI-Chatbot Architectures and Evaluation: Analyzing architectures and evaluation methods for conversational AI systems, including

chatbots, virtual assistants, and dialogue systems." *Australian Journal of Machine Learning Research & Applications* 1.1 (2021): 13-20.

34. Ponnusamy, Sivakumar, and Dinesh Eswararaj. "Modernization of Legacy Applications and Data: A Comprehensive Review on Implementation Challenges, Effective Strategies and Best Practices." (2024): 81-106.
35. Maruthi, Srihari, et al. "Language Model Interpretability-Explainable AI Methods: Exploring explainable AI methods for interpreting and explaining the decisions made by language models to enhance transparency and trustworthiness." *Australian Journal of Machine Learning Research & Applications* 2.2 (2022): 1-9.
36. Dodda, Sarath Babu, et al. "Federated Learning for Privacy-Preserving Collaborative AI: Exploring federated learning techniques for training AI models collaboratively while preserving data privacy." *Australian Journal of Machine Learning Research & Applications* 2.1 (2022): 13-23.
37. Zanke, Pankaj. "Machine Learning Approaches for Credit Risk Assessment in Banking and Insurance." *Internet of Things and Edge Computing Journal* 3.1 (2023): 29-47.
38. Maruthi, Srihari, et al. "Temporal Reasoning in AI Systems: Studying temporal reasoning techniques and their applications in AI systems for modeling dynamic environments." *Journal of AI-Assisted Scientific Discovery* 2.2 (2022): 22-28.
39. Yellu, Ramswaroop Reddy, et al. "Transferable Adversarial Examples in AI: Examining transferable adversarial examples and their implications for the robustness of AI systems." *Hong Kong Journal of AI and Medicine* 2.2 (2022): 12-20.
40. Reddy Yellu, R., et al. "Transferable Adversarial Examples in AI: Examining transferable adversarial examples and their implications for the robustness of AI systems. Hong Kong Journal of AI and Medicine, 2 (2), 12-20." (2022).
41. Zanke, Pankaj, and Dipti Sontakke. "Artificial Intelligence Applications in Predictive Underwriting for Commercial Lines Insurance." *Advances in Deep Learning Techniques* 1.1 (2021): 23-38.
42. Singh, Amarjeet, and Alok Aggarwal. "Artificial Intelligence based Microservices Pod configuration Management Systems on AWS Kubernetes Service." *Journal of Artificial Intelligence Research* 3.1 (2023): 24-37.